
Investors & Partners
Partner with us to advance innovative gene therapies for neurodegenerative disease.
Who we are
Celosia Therapeutics is a biotechnology company developing precision gene therapies for neurodegenerative diseases, including ALS and FTD.
Built on decades of neuroscience research, our work focuses on targeting the underlying genetic and cellular drivers of disease, with the goal of modifying the neuronal microenvironment to halt, reverse and defeat neurodegenerative disease.

Company highlights






Our programs
Celosia have various programs focused on key disease drivers across neurodegenerative conditions.
Stage: IND Submission (First-in-patient dosing expected Q2)
CTX1000 is Celosia’s lead, first-in-class gene therapy targeting toxic TDP-43, a core driver of ALS and FTD. By addressing the underlying disease mechanism rather than symptoms, it has the potential to slow or halt neurodegeneration. Its progression to IND submission and planned first-in-patient dosing provides investors with a clear near-term clinical milestone and an opportunity to be part of a pioneering therapy in a high-unmet-need space.
Stage: Preclinical
CTX2000 is a gene therapy program targeting disease-specific molecular mechanisms in ALS to protect nerve cells and slow disease progression. Its preclinical success positions the program for rapid advancement toward clinical studies, offering investors insight into a diversified pipeline and multiple potential value inflection points in ALS.
Stage: Discovery
CTX3000 focuses on tau-driven neurodegeneration in Alzheimer’s disease. By aiming to preserve cognitive function through a precision genetic medicine, the program addresses a major global health challenge. For investors, this early-stage program represents a long-term opportunity to enter a high-impact, high-value market with strong scientific rationale.
Stage: Discovery
CTX4000 is designed to restore neuronal balance in severe epilepsy syndromes by targeting underlying molecular drivers of hyperexcitability. This program highlights Celosia’s broader expertise in neurological disorders and offers investors early exposure to innovative therapies for rare but high-need patient populations, diversifying the company’s pipeline potential.
Clinical Pipeline

Let’s advance
what’s possible
together
Celosia Therapeutics is building the next generation of gene therapies for ALS, FTD, and Alzheimer’s disease. Connect with us to discuss partnership or investment opportunities.
